SC66 has been shown to inhibit the binding of NF-YA and c/ERBβ to COL11A1 promoter, thereby reducing the chemotherapy resistance induced by Twist1 and Mcl-1, and inhibiting the expression of MMP3 and the invasion ability of cancer cells. Here, COL11A1 is linked to cancer.